Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Suppressive effects of resveratrol on epithelial-mesenchymal transition in the YKG1 glioblastoma cell-line

Mehmet Bilgehan Pektas, Esra Aslan, Fatma Firat, Cigdem Karaca, Hilal Guzel, Serhat Yildizhan.




Abstract

Glioblastoma multiforme (GBM), is an aggressive tumor type with high mortality and morbidity, which a curative treatment method has not been developed yet. Although Epithelial-mesenchymal transition (EMT) is a known mechanism to be effective in the cancer process, the EMT process seen in these cells has not been fully explained yet. Resveratrol is a flavonoid and has been reported to have positive effects on different types of cancer. In this study, we aimed to compare the effects of resveratrol on EMT in YKG1 GBM cell line. Different doses of resveratrol (50 and 100 µM) were applied to YKG1 glioblastoma cells, and their viability was calculated and immunocytochemical analyzes were evaluated. According to results, it was observed that the 100 µM resveratrol dose significantly reduced the viability compared to the 50 µM resveratrol dose. It was determined that Vimentin and N-Cadherin H scores of 100 µM Resveratrol dose decreased and E-cadherin and Claudin-1 values increased compared to the other groups. The results showed that increasing resveratrol dose was more effective on EMT on glioblastoma cell lines in a dose-dependent manner.

Key words: Epithelial-mesenchymal transition, Glioblastoma multiforme, Resveratrol, YKG1






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.